BAY U3405, a Potent and Selective Thromboxane A2 Receptor Antagonist on Airway Smooth Muscle in Vitro

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1991 Nov 1

PMID 1839139

Citations 12

Authors

M G McKenniff

P Norman

N J Cuthbert

P J Gardiner

Affiliations

Soon will be listed here.

Abstract

1. BAY u3405 (3(R)-[[(4-fluorophenyl) sulphonyl]amino]-1,2,3,4- tetrahydro-9H-carbazole-9-propanoic acid) has been evaluated on airway smooth muscle, from a number of species including man, for its thromboxane A2 (TXA2) antagonist activity. 2. BAY u3405 was a potent, and competitive, antagonist of the TXA2-mimetic U46619-induced contractions of human, guinea-pig, rat and ferret airway smooth muscle with pA2 values between 8.0 and 8.9 and with no inherent contractile activity (10(-9)-10(-4) M). 3. The TXA2 antagonist activity of BAY u3405 was stereoselective. Its (S)-enantiomer, BAY u3406, was approximately 50 fold less effective against U46619 on guinea-pig and human airway smooth muscle. 4. BAY u3405 also competitively antagonized contractions of guinea-pig airway smooth muscle induced by prostaglandin D2 (PGD2) or its metabolite 9 alpha, 11 beta-PGF2. On human and ferret airway smooth muscle it abolished contractions induced by PGD2, PGF2 alpha and 16,16-dimethyl-PGE2. 5. A high concentration (10(-6) M) of BAY u3405 had no effect on the contraction, or relaxation, of airway smooth muscle induced by a range of other agonists, nor did BAY u3405 have any effect on other prostanoid receptor types (DP, EP2, FP or IP). 6. BAY u3405, in contrast to some other TXA2 antagonists, is a potent and selective antagonist on a wide range of airways including human. This high affinity, and the oral activity of the compound described elsewhere, suggest it may be an appropriate tool to investigate the role of prostanoids in airway diseases such as asthma.

Citing Articles

Ramatroban-Based Analogues Containing Fluorine Group as Potential F-Labeled Positron Emission Tomography (PET) G-Protein Coupled Receptor 44 (GPR44) Tracers.

Huang L, Huang K, Tu J, Kandeel F, Li J Molecules. 2021; 26(5).

PMID: 33800801 PMC: 7961607. DOI: 10.3390/molecules26051433.

Regulation of [³H]d-aspartate release by the 5-F(2t)-isoprostane and its 5-epimer in isolated bovine retina.

Jamil J, Wright A, Harrison N, Kegey E, Flowers A, Flyod N Neurochem Res. 2011; 37(3):574-82.

PMID: 22081406 DOI: 10.1007/s11064-011-0645-5.

Prostanoid receptor antagonists: development strategies and therapeutic applications.

Jones R, Giembycz M, Woodward D Br J Pharmacol. 2009; 158(1):104-45.

PMID: 19624532 PMC: 2795261. DOI: 10.1111/j.1476-5381.2009.00317.x.

Using guinea pigs in studies relevant to asthma and COPD.

Canning B, Chou Y Pulm Pharmacol Ther. 2008; 21(5):702-20.

PMID: 18462968 PMC: 2882537. DOI: 10.1016/j.pupt.2008.01.004.

The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.

Pettipher R Br J Pharmacol. 2007; 153 Suppl 1:S191-9.

PMID: 17965752 PMC: 2268053. DOI: 10.1038/sj.bjp.0707488.

References

ARUNLAKSHANA O, SCHILD H . Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959; 14(1):48-58. PMC: 1481829. DOI: 10.1111/j.1476-5381.1959.tb00928.x. View

Walker J . Interrelationships of SRS-A production and arachidonic acid metabolism in human lung tissue. Adv Prostaglandin Thromboxane Res. 1980; 6:115-9. View

Francis H, Greenham S, Patel U, Thompson A, Gardiner P . BAY u3405 an antagonist of thromboxane A2- and prostaglandin D2-induced bronchoconstriction in the guinea-pig. Br J Pharmacol. 1991; 104(3):596-602. PMC: 1908239. DOI: 10.1111/j.1476-5381.1991.tb12475.x. View

Maynard K, Lincoln J, Burnstock G . Sympathetic neurotransmission in the rabbit isolated central ear artery is affected as early as one week following a single dose of X-irradiation. Br J Pharmacol. 1991; 102(1):23-6. PMC: 1917892. DOI: 10.1111/j.1476-5381.1991.tb12126.x. View

Rosentreter U, Boshagen H, Seuter F, Perzborn E, Fiedler V . Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer. Arzneimittelforschung. 1989; 39(12):1519-21. View

Lumley P, White B, Humphrey P . GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989; 97(3):783-94. PMC: 1854582. DOI: 10.1111/j.1476-5381.1989.tb12017.x. View

McKenniff M, Rodger I, Norman P, Gardiner P . Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur J Pharmacol. 1988; 153(2-3):149-59. DOI: 10.1016/0014-2999(88)90601-2. View

Giles H, Leff P, Bolofo M, Kelly M, Robertson A . The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br J Pharmacol. 1989; 96(2):291-300. PMC: 1854342. DOI: 10.1111/j.1476-5381.1989.tb11816.x. View

Beasley R, Featherstone R, Church M, Rafferty P, Varley J, Harris A . Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction. J Appl Physiol (1985). 1989; 66(4):1685-93. DOI: 10.1152/jappl.1989.66.4.1685. View

10.

Ogletree M . Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987; 46(1):133-8. View

11.

Mais D, DeHoll D, Sightler H, Halushka P . Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels. Eur J Pharmacol. 1988; 148(3):309-15. DOI: 10.1016/0014-2999(88)90108-2. View

12.

Eglen R, Whiting R . The action of prostanoid receptor agonists and antagonists on smooth muscle and platelets. Br J Pharmacol. 1988; 94(2):591-601. PMC: 1854006. DOI: 10.1111/j.1476-5381.1988.tb11565.x. View

13.

Shephard E, Malan L, Macfarlane C, Mouton W, Joubert J . Lung function and plasma levels of thromboxane B2, 6-ketoprostaglandin F1 alpha and beta-thromboglobulin in antigen-induced asthma before and after indomethacin pretreatment. Br J Clin Pharmacol. 1985; 19(4):459-70. PMC: 1463826. DOI: 10.1111/j.1365-2125.1985.tb02671.x. View

14.

Wenzel S, Larsen G, Johnston K, Voelkel N, Westcott J . Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 1990; 142(1):112-9. DOI: 10.1164/ajrccm/142.1.112. View

15.

Coleman R, Humphrey P, Kennedy I, Levy G, Lumley P . Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981; 73(3):773-8. PMC: 2071689. DOI: 10.1111/j.1476-5381.1981.tb16814.x. View

16.

Lefer A, Smith 3rd E, Araki H, Smith J, Aharony D, Claremon D . Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci U S A. 1980; 77(3):1706-10. PMC: 348566. DOI: 10.1073/pnas.77.3.1706. View

17.

KUEHL Jr F, Dougherty H, HAM E . Interactions between prostaglandins and leukotrienes. Biochem Pharmacol. 1984; 33(1):1-5. DOI: 10.1016/0006-2952(84)90362-9. View

18.

Fairfax A, Hanson J, Morley J . The late reaction following bronchial provocation with house dust mite allergen. Dependence on arachidonic acid metabolism. Clin Exp Immunol. 1983; 52(2):393-8. PMC: 1535850. View

19.

Tymkewycz P, Jones R, Wilson N, Marr C . Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements. Br J Pharmacol. 1991; 102(3):607-14. PMC: 1917959. DOI: 10.1111/j.1476-5381.1991.tb12220.x. View